You walk into a room and forget why. That has happened for years. Lately, though, you lose the thread of conversations more often, and last month you missed a dentist appointment you had written on the calendar. Your sister says it happens to everyone. A search engine hints at something worse.
Both answers skip the middle. Between ordinary forgetting and dementia, researchers recognize two named states most people have never heard of. In subjective cognitive decline, you notice a change that standard tests cannot find. In mild cognitive impairment, tests find a real deficit, but you still run your own life.
Neither state is a one-way door. In a 2025 analysis of 89 long-term studies, about half of people diagnosed with mild cognitive impairment were in the same place years later, and in community studies more than a quarter had returned to normal scores. Where a person is diagnosed shapes those odds more than most people would guess.
Two named states between normal and dementia
Clinicians sort thinking problems with two questions: what do careful tests show, and can the person still manage daily life without help?
Dementia sits at the far end. Thinking problems are severe enough to take away independence.
Mild cognitive impairment (MCI) sits one step back. The US criteria, reproduced in a primary care guideline the Alzheimer’s Association published in late 2024, require four things: a concern that thinking has changed, objective evidence of impairment in at least one area such as memory or language, independence in everyday functioning that is still preserved, and no dementia. A person with MCI may take longer over the bills or a complicated recipe, but still does them.
Subjective cognitive decline (SCD) is the stop nearest to normal. A 2020 paper in The Lancet Neurology from the Subjective Cognitive Decline Initiative, an international research group whose first author is Frank Jessen of the University of Cologne, sets out two criteria. You experience a persistent decline from your own earlier level that is not tied to an acute event such as an illness or an operation. And you score normally on standardized tests, judged against people of your age, sex and education. Nobody else has to notice.
On testing, then, a person with SCD looks the same as a person without it. The only difference is the experience of decline. SCD is not a diagnostic category in ICD-10, ICD-11 or DSM-5, the main classification systems, and the group says plainly that it does not propose screening anyone for it.
| State | What standard tests show | Everyday independence | A clinical diagnosis? |
|---|---|---|---|
| Subjective cognitive decline | Normal for age, sex and education | Intact | No |
| Mild cognitive impairment | Below expected in one or more areas | Preserved | Yes |
| Dementia | Impaired | Lost or reduced | Yes |
The slower processing of healthy aging, which comes before either state, is covered in our article on normal brain aging.
How common each state is
Self-noticed decline is common, and it is not only an older person’s worry.
The Centers for Disease Control and Prevention tracks it through the Behavioral Risk Factor Surveillance System, a large state-run telephone survey. Adults 45 and older are asked whether, over the past year, confusion or memory loss has been happening more often or getting worse. In 2015 and 2016, 11.2% said yes. The share was 10.4% at ages 45 to 54 and lowest, 9.9%, at 65 to 74, before rising to 14.3% at 75 and older. Only 45.4% of them had discussed it with a health care professional, though about half said it had cost them chores, work or social activities.
A 2025 analysis of 2022 survey data from 18 states, published in the CDC’s journal Preventing Chronic Disease, found the same age pattern: 12.2% of adults 45 to 64 reported decline, compared with 10.1% of those 65 and older.
The Alzheimer’s Association’s November 2025 factsheet, drawing on 2023 and 2024 data from 47 states, puts the share at 16.6%, with 58.1% of those people worried about it. Worry ran higher among younger respondents: about two-thirds of people 45 to 59 who reported decline were worried, against fewer than half of those 80 and older.
Do not read those figures as a rising trend. They come from different years and groups of states, and the CDC notes that participating states vary by year. Both organizations stress that the survey measures self-reported change, not a medical condition.
Ask more probing questions and the share climbs. The 2020 Lancet Neurology paper cites population studies in which 50% to 80% of people 70 and older who test normal report some perceived decline when asked.
MCI is less common but far from rare. The best national estimate comes from the Health and Retirement Study, a long-running NIH-funded survey. In 2016, 3,496 Americans 65 and older completed a full battery of thinking tests, and someone who knew each of them was interviewed too. Writing in JAMA Neurology in 2022, researchers led by Jennifer J. Manly of Columbia University used a standard algorithm to classify 22% as having MCI and 10% as having dementia. Each additional five years of age raised the odds of MCI by about 17%, and each extra year of schooling lowered them slightly.
Other figures you may see, roughly 10% to 20% of people over 65 on the National Institute on Aging’s Alzheimers.gov and 12% to 18% of people 60 and older from the Alzheimer’s Association, use different age bands and methods. They are not a dispute.
When the worry is about your own memory
Self-noticed decline is a real risk signal, but a weak one for any single person.
A 2014 meta-analysis in Acta Psychiatrica Scandinavica by A. J. Mitchell and colleagues pooled 28 studies that followed 29,723 people, average age 71.6, for nearly five years. People who complained about their memory despite normal test results went on to develop dementia at about 2.3% a year, roughly double the rate in people without complaints. Over four years or more, 14.1% developed dementia. The yearly rate looked similar in community and clinic samples.
So the risk roughly doubles, and most people still do not progress. The Subjective Cognitive Decline Initiative’s counseling advice to clinicians puts it this way: “We also propose explaining that SCD can resolve spontaneously, and that most individuals with SCD will not experience objective cognitive decline in the near future.”
The same paper describes features, which it calls “SCD plus,” that make a self-noticed change more likely to reflect early brain disease. Grouped by what you can observe:
- What changed. Memory in particular, rather than other thinking skills.
- When and how. A change that began within the past five years, started after age 60, and has stayed consistent rather than coming and going.
- Who is paying attention. The person is worried about it, someone else has confirmed the change, and the person has sought medical help because of it.
The age detail cuts both ways. Before 60, the authors note, a noticed decline is more likely to trace to another, often reversible cause, such as depression.
The observer detail matters too. A 2022 meta-analysis in Ageing Research Reviews by Lucía Pérez-Blanco and colleagues found that complaints from the person and from someone close to them were both linked to later progression, somewhat more strongly for the outside reports. If your spouse sees a change you don’t, that observation carries weight.
Where mild cognitive impairment leads
The fullest answer comes from a 2025 systematic review in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring by Simone Salemme and colleagues, several of them at Italy’s National Institute of Health. They pooled 89 studies published from 2004 to 2023, covering 33,115 people with MCI followed for at least three years, 5.2 years on average.
The outcomes split sharply by setting:
| Outcome during follow-up | Clinics, including memory clinics | Community (population) studies |
|---|---|---|
| Developed dementia | 41.5% | 27.0% |
| Yearly rate of dementia | 10.9% | 5.9% |
| Stayed stable | 49.3% | 49.8% |
| Returned to normal thinking | 8.7% | 28.2% |
Each figure was pooled from a different subset of studies, so the columns do not add up to 100%. The steadiest finding is stability: about half of people stayed where they were, wherever they were diagnosed. An earlier 2016 meta-analysis of 25 studies, in the Journal of the American Medical Directors Association, found the same split for reversion, 8% in clinic studies and 25% in population studies.
Why does setting matter so much? The review’s authors note that specialist clinics may see people with more advanced disease or greater frailty, while population studies find MCI by testing whole communities, which also catches milder and more changeable cases. The yearly rate of dementia also fell the longer studies ran, from 13.1% in three-year clinic studies to 7.8% in those lasting more than five years.
That explains a confusing mismatch online. Alzheimers.gov estimates that roughly one or two in 10 people 65 and older with MCI develop dementia over a year, and the Alzheimer’s Association puts it at 10% to 15% a year. Those figures sit close to the clinic estimate. Community studies run at about half that pace.
Among clinic patients, 35.3% of people with MCI developed Alzheimer’s dementia, 5.3% vascular dementia, 2.8% dementia with Lewy bodies and 1.2% frontotemporal dementia. MCI describes where thinking stands today. It is not a verdict on which disease, if any, lies underneath. Alzheimers.gov lists treatable causes, including a bad reaction to a medication, emotional problems, heavy drinking, and blood clots or tumors in the brain, and the Alzheimer’s Association notes that a medication causing cognitive problems can lead to a mistaken MCI diagnosis.
Returning to normal is good news, not an all-clear
When a follow-up test comes back normal, it is tempting to call it a false alarm. Two careful studies differ on how much reassurance that deserves.
The Mayo Clinic Study of Aging, a population study in Minnesota, followed 534 people 70 and older with MCI, testing them every 15 months for a median of 5.1 years. In the 2014 report in Neurology by Rosebud O. Roberts and colleagues, 38% reverted to normal at some point. But 65% of those who reverted later developed MCI or dementia again, and their risk of dementia was 6.6 times that of people who had never been impaired. Reversion was less likely in people who carried the APOE e4 gene variant, people whose MCI centered on memory or spanned several areas, and people with poorer scores.
A 2025 study in BMC Medicine by Hai-Hong Yu and colleagues at Qingdao University was more reassuring about Alzheimer’s disease in particular. It drew on the Alzheimer’s Disease Neuroimaging Initiative, a research study run at sites in the US and Canada, whose volunteers, the authors note, were relatively highly educated rather than a cross-section of the community. About 18% of participants who began with MCI were back to normal within two years. Over the following six years of tracking 796 people, those who had reverted had about a 90% lower risk of Alzheimer’s dementia than people whose MCI persisted, and no significant difference in that risk from people who had always tested normal. Compared with those people, though, they had more than three times the risk of slipping back into MCI or developing Alzheimer’s.
The studies differ in who took part and what they counted: dementia of any cause in a Minnesota population sample versus Alzheimer’s dementia in research volunteers, with reversion counted at any visit in one and over a fixed two-year window in the other. On the broader question, whether someone who reverts is as safe as someone who never had MCI, both found extra risk. Neither cancels the other. The defensible reading is that reversion is a favorable sign that still calls for follow-up. Alzheimers.gov suggests seeing a doctor every six to 12 months after an MCI diagnosis to track changes, and the Alzheimer’s Association suggests re-evaluation every six months.
Memory is not the only early signal
MCI comes in two broad forms. In the Alzheimer’s Association’s terms, amnestic MCI mainly affects memory. Nonamnestic MCI affects other thinking skills, such as making sound decisions, judging the time or order of steps a complicated task needs, or visual perception. In the 2025 review, amnestic MCI tracked the overall clinic picture: 40.1% progressed to dementia, 47.8% stayed stable and 14.9% reverted.
Mild behavioral impairment (MBI), a newer idea, proposes that some brain diseases first show up as changes in mood or behavior rather than memory. In 2016, a working group of the International Society to Advance Alzheimer’s Research and Treatment, headed by Zahinoor Ismail of the University of Calgary, published provisional research criteria in Alzheimer’s & Dementia. They describe changes that begin later in life and persist, at least on and off, for six months or more. The changes fall into five areas: mood and anxiety; drive and motivation; impulse control, which can show up as agitation; social conduct, such as new disinhibition; and perception or thought, including beliefs that are out of character. The changes must cause at least minimal trouble in daily life and must not be better explained by another psychiatric disorder. MCI can be present at the same time; dementia rules MBI out.
A 2021 meta-analysis in Psychogeriatrics by Yining Pan and colleagues found MBI in 45.5% of people with MCI and 17.0% of people with normal cognition. A 2026 meta-analysis in the Journal of Alzheimer’s Disease, covering studies through November 2025, found MBI linked to a higher risk of dementia despite wide differences between studies, with apathy and mood changes the strongest predictors.
Hold this one loosely. The criteria are provisional, and their authors acknowledge that nobody yet knows how well they separate early brain disease from depression, anxiety and other psychiatric conditions that begin late in life. They also note that some lasting personality changes after 50 are ordinary adaptations to a changed life. A new low mood at 62 deserves care as low mood, whatever else it may or may not mean. If it comes with thoughts of suicide, call or text 988 to reach the Suicide and Crisis Lifeline.
What to write down while you wait for the appointment
Book the visit first; the notes can come together while you wait. A clinician sorting SCD from MCI needs the details researchers use, and you and the people around you are the only source for most of them.
- The kind of change. Recent events, word-finding, following conversation, planning multistep tasks, getting around, or mood and behavior. Mark which appeared first.
- Start and pace. The month you first noticed it, and whether it has crept, held steady, come and gone, or jumped.
- The cost. One or two tasks that now take longer, need reminders or have been handed to someone else. This is the line between MCI and dementia, and the people living it see it best.
- A second account. Ask someone who sees you often to write their own version, separately from yours. Their view can differ, and the research above suggests it matters.
- What else was going on. Poor sleep or loud snoring, low mood or anxiety, drinking, a recent illness, and any medicine started or changed shortly before the change began. The Alzheimer’s Association guideline names obstructive sleep apnea, medicines that can impair thinking, mood disorders and heavy drinking among common contributors. Whether a particular medicine plays a part is a question for whoever prescribed it.
How a clinician sorts through those contributors is laid out in our brain fog article. The visit itself, from Medicare coverage to the new blood tests, is the subject of our guide to getting memory problems assessed, and the brief screening tests get their own scrutiny in the piece on cognitive testing.
When to get help sooner
- A change that persists or worsens, noticed by you or by someone close to you. The Association’s primary care guideline treats any reported change in thinking, behavior or daily function as grounds for an evaluation.
- Signs the National Institute on Aging associates with MCI, such as misplacing things frequently, missing events you meant to attend, or reaching for words more than your peers do.
- New, lasting changes in personality or mood in midlife or later.
- Sudden confusion, trouble speaking or trouble understanding speech. Treat these as possible stroke signs: the CDC’s instruction is an ambulance through 911, not a drive to the hospital.
The most useful thing to know
Subjective cognitive decline and mild cognitive impairment describe where thinking stands now, not where it must go. A self-noticed change roughly doubles dementia risk, yet most people who notice one do not decline soon. About half of people with MCI hold steady for years, and in community studies more than a quarter return to normal, though a return deserves follow-up rather than a farewell.
The practical step is the same at every point on that spectrum. When a change has lasted, write down what changed and when, bring a second witness, and have it evaluated. Calling it normal aging is a conclusion that belongs at the end of that process, not the start.
Sources
- Centers for Disease Control and Prevention (Morbidity and Mortality Weekly Report). “Taylor CA, Bouldin ED, McGuire LC. "Subjective Cognitive Decline Among Adults Aged ≥45 Years, United States, 2015–2016." MMWR, 2018;67(27):753-757.” cdc.gov
- Centers for Disease Control and Prevention. “Behavioral Risk Factor Surveillance System (BRFSS) Cognitive Decline Module.” cdc.gov
- Preventing Chronic Disease (Centers for Disease Control and Prevention). “Alshanbari MH, Cheney AM, Alhazmi HA, Bouldin ED. "The Impact of Oral Health and Dental Services on the Prevalence of Subjective Cognitive Decline Among Middle-Aged and Older US Adults: Behavioral Risk Factor Surveillance System, 2022." Prev Chronic Dis, 2025;22. DOI: 10.5888/pcd22.250083.” cdc.gov
- Alzheimer's Association. “Subjective Cognitive Decline in the U.S.: Data from the BRFSS (factsheet, November 2025).” alz.org
- The Lancet Neurology. “Jessen F et al. "The characterisation of subjective cognitive decline." Lancet Neurol, 2020. PubMed. DOI: 10.1016/S1474-4422(19)30368-0.” pubmed.ncbi.nlm.nih.gov
- Alzheimer's & Dementia (Alzheimer's Association). “Atri A et al. "Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care." Alzheimers Dement, 2025 (online December 2024). PubMed. DOI: 10.1002/alz.14333.” pubmed.ncbi.nlm.nih.gov
- JAMA Neurology. “Manly JJ et al. "Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project." JAMA Neurol, 2022. PubMed. DOI: 10.1001/jamaneurol.2022.3543.” pubmed.ncbi.nlm.nih.gov
- National Institute on Aging (Alzheimers.gov). “What Is Mild Cognitive Impairment? (updated June 17, 2026).” alzheimers.gov
- Alzheimer's Association. “Mild Cognitive Impairment (MCI).” alz.org
- Acta Psychiatrica Scandinavica. “Mitchell AJ et al. "Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis." Acta Psychiatr Scand, 2014. PubMed. DOI: 10.1111/acps.12336.” pubmed.ncbi.nlm.nih.gov
- Ageing Research Reviews. “Pérez-Blanco L et al. "Do informant-reported subjective cognitive complaints predict progression to mild cognitive impairment and dementia better than self-reported complaints in old adults? A meta-analytical study." Ageing Res Rev, 2022. PubMed. DOI: 10.1016/j.arr.2022.101772.” pubmed.ncbi.nlm.nih.gov
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. “Salemme S et al. "The prognosis of mild cognitive impairment: A systematic review and meta-analysis." Alzheimers Dement (Amst), 2025. PubMed. DOI: 10.1002/dad2.70074.” pubmed.ncbi.nlm.nih.gov
- Journal of the American Medical Directors Association. “Canevelli M et al. "Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis." J Am Med Dir Assoc, 2016. PubMed. DOI: 10.1016/j.jamda.2016.06.020.” pubmed.ncbi.nlm.nih.gov
- Neurology. “Roberts RO et al. "Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal." Neurology, 2014. PubMed. DOI: 10.1212/WNL.0000000000000055.” pubmed.ncbi.nlm.nih.gov
- BMC Medicine. “Yu HH et al. "Dissecting the clinical and pathological prognosis of MCI patients who reverted to normal cognition: a longitudinal study." BMC Med, 2025. PubMed. DOI: 10.1186/s12916-025-04092-0.” pubmed.ncbi.nlm.nih.gov
- Alzheimer's Disease Neuroimaging Initiative. “About ADNI.” adni.loni.usc.edu
- Alzheimer's & Dementia (Alzheimer's Association). “Ismail Z et al. "Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment." Alzheimers Dement, 2016. PubMed. DOI: 10.1016/j.jalz.2015.05.017.” pubmed.ncbi.nlm.nih.gov
- Psychogeriatrics. “Pan Y et al. "Prevalence of mild behavioural impairment: a systematic review and meta-analysis." Psychogeriatrics, 2021. PubMed. DOI: 10.1111/psyg.12636.” pubmed.ncbi.nlm.nih.gov
- Journal of Alzheimer's Disease. “Sassi KLM et al. "Mild behavioral impairment and risk of incident dementia: A systematic review and meta-analysis." J Alzheimers Dis, 2026. PubMed. DOI: 10.1177/13872877261480315.” pubmed.ncbi.nlm.nih.gov
- Centers for Disease Control and Prevention. “Signs and Symptoms of Stroke (reviewed May 19, 2026).” cdc.gov